XENE Files NDA for Epilepsy Drug, Falls on Depression Studies’ Setback
Xenon Pharmaceuticals XENE announced that it has submitted a new drug application (NDA) to the FDA for azetukalner,…
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS…
Lessons for Parkinson’s From MS, and Vice Versa
This transcript has been edited for clarity. Indu Subramanian, MD: Hi, everyone. Welcome to Medscape. I’m so excited…
Rectal Cancer Survival Not Tied to pCR
TOPLINE: According to a meta-analysis of randomized clinical trials (RCTs), pathologic complete response (pCR) was not associated with…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
Is the Supplement Ready for Clinical Use?
Popular among bodybuilders, creatine supplementation is gaining traction for its potential use beyond athletic performance. Researchers are exploring…